Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Talfirastide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.59 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 4/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | CALCR | P30988 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29701258 | 0.97 | AGTR2 (0.55) | AGTR1AGTR2C5AR1MC4REPHA2 | |
| SCHEMBL29602954 | 0.95 | C5AR1 (0.55) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL9510693 | 0.95 | AGTR1 (0.60) | AGTR1AGTR2C5AR1MC4REPHA2 | |
| SCHEMBL29972916 | 0.95 | AGTR1 (0.62) | AGTR1AGTR2C5AR1EPHA2NTSR2 | |
| SCHEMBL15928128 | 0.95 | AGTR2 (0.59) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL30901127 | 0.94 | C5AR1 (0.52) | AGTR1AGTR2C5AR1MC4REPHA2 | |
| Angiotensin-Ii SCHEMBL29973063 | 0.94 | AGTR2 (0.62) | AGTR1AGTR2C5AR1EPHA2NTSR2 | |
| SCHEMBL7052378 | 0.94 | AGTR2 (0.65) | AGTR1AGTR2C5AR1EPHA2NTSR2 | |
| SCHEMBL10924118 | 0.94 | AGTR1 (0.53) | AGTR1AGTR2C5AR1MC4REPHA2 | |
| Angiotensin Ii SCHEMBL9013957 | 0.93 | AGTR2 (0.69) | AGTR1AGTR2C5AR1EPHA2NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250027942-A1 | COVID-19 THERANOSTIC | Université Libre de Bruxelles (BE) | 2025-01-23 | — | — | US | disclosed |
| US-20240123023-A1 | PHARMACEUTICAL ANGIOTENSIN-(1-7) COMPOSITIONS IN THE TREATMENT OF (SARS)-COV- OR (SARS)-COV-2-INFECTION RELATED DISEASES | CU PHARMACEUTICALS GMBH (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-4333800-A1 | PHARMACEUTICAL ANGIOTENSIN-(1-7) COMPOSITIONS IN THE TREATMENT OF (SARS)-COV- OR (SARS)-COV-2-INFECTION RELATED DISEASES | CU pharmaceuticals GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| US-20240067973-A1 | Oligonucleotide for reducing the expression of angiotensin-converting enzyme 2 (ACE2) and its use for treating viral infection | THE FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSITY (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-117500924-A | Oligonucleotides for reducing angiotensin converting enzyme 2 (ACE 2) expression and their use in treating viral infections | 赛卡纳制药股份两合公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117120417-A | Methods and agents for stimulating mitochondrial turnover to treat diseases | 容量生物公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117024480-A | P-hydroxyphenylhydrazine compound phosphide and method for preparing Ang1-7 peptide compound assisted by same | 西北工业大学 | 2023-11-10 | — | — | CN | disclosed |
| EP-4271814-A1 | OLIGONUCLEOTIDE FOR REDUCING THE EXPRESSION OF ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) AND ITS USE FOR TREATING VIRAL INFECTION | The First Affiliated Hospital of Sun Yat-sen University (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20140220063-A1 | VACCINE COMPOSITION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220063-A1 | VACCINE COMPOSITION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220058-A1 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140220058-A1 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION | NITTO DENKO CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2762159-A1 | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (JP) | 2014-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | AGTR1 242/4885AGTR2 337/4885C5AR1 939/4885 |
| US-20140220100-A1 | VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | ERBB2, EGFR, ERBB3 | AGTR1 2764/4885AGTR2 2066/4885C5AR1 79/4885 |
| US-20140220058-A1 | VACCINE COMPOSITION FOR TRANSDERMAL OR MUCOSAL ADMINISTRATION | CD69, TSLP, MUC1 | AGTR1 642/4885AGTR2 614/4885C5AR1 104/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | AGTR1 1006/4885AGTR2 1203/4885C5AR1 3824/4885 |
| US-20140220055-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION | TAP1, TAP2, MICA | AGTR1 1355/4885AGTR2 1622/4885C5AR1 212/4885 |
| US-20140220079-A1 | VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, ERBB2, TLR5 | AGTR1 3510/4885AGTR2 2837/4885C5AR1 198/4885 |
| US-20140220059-A1 | WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION | MUC1, TAP1, MICA | AGTR1 1941/4885AGTR2 2376/4885C5AR1 606/4885 |
| US-20140220063-A1 | VACCINE COMPOSITION | MYD88, IRF3, CD14 | AGTR1 2733/4885AGTR2 2982/4885C5AR1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.